BOSTON, Aug. 15, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the full market release of its VASCADE MVP® XL mid-bore venous closure system. The VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable c ...

Haemonetics Corporation (HAE) delivered adjusted earnings per share (EPS) of $1.02 in the first quarter of fiscal 2025, down 2.9% year over year. The bottom line missed the Zacks Consensus Estimate by 0.9%. On a GAAP basis, the EPS was 74 cents compared with 80 cents in the prior-year quarter. Total Revenues Revenues increased 8% (up 2.8% on an organic basis) to $336.2 million in the first quarter of fiscal 2025. The top line beat the Zacks Consensus Estimate by 0.1%. Segments in Detail At Plasma, revenues ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a ...

Haemonetics (HAE) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

Haemonetics Corporation (NYSE:HAE) Q1 2025 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Olga Guyette – Vice President, Investor Relations and Treasury Chris Simon – Chief Executive Officer James D’Arecca – Chief Financial Officer Conference Call Participants Anthony Petrone – Mizuho Americas Mike Matson – Needham Andrew Cooper – Raymond James Larry Solow – CJS Securities Joanne Wuensch – Citi Michael Petusky – Barrington Research Operator Thank you for standing by, and welcome to ...

Haemonetics (HAE) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -0.97%. A quarter ago, it was expected that this provider blood management systems for health care providers and blood collectors would post earnings of $0.88 per share when it actually produced earnings of $0.90, deli ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 | --- | --- | |----------------------------------------------------------------------------|------------------------------------------| | Massachusetts | 04-2882273 | ...

HAEMONETICS® 1 Exhibit 99.1 Investor Contacts Olga Guyette, Vice President-Investor Relations & Treasury (781) 356-9763 olga.guyette@haemonetics.com | --- | |----------------------------------------------| | | | Media Contact | | Josh Gitelson, Sr. Director-Communications | | (781) 356-9776 josh.gitelson@haemonetics.com | David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk@haemonetics.com Haemonetics Reports First Quarter Fiscal 2025 Results; Reaffirms Fiscal 2025 Guidance Boston, MA, August ...

Shares of Haemonetics (HAE) have gained 2.4% over the past four weeks to close the last trading session at $86.20, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $112.17 indicates a potential upside of 30.1%. The average comprises six short-term price targets ranging from a low of $94 to a high of $125, with a standard deviation of $10.87. While the lowest estimate indicates an ...

CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has ser ...